Valuation dashboard for Immuneering Corporation (IMRX) with P/E N/A, P/B 1.50, EV/EBITDA -2.24 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $4.45, IMRX has negative trailing earnings (P/E not meaningful) and an ROE of -27.15%. Market capitalisation stands at $162M.
Balance sheet quality for IMRX: current ratio of 17.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.50 |
| EV / EBITDA | -2.24 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $2.80 |
| vs Current Price | -37.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IMRX | Immuneering Corporation | $162M | 1.50 | -27.2% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $4.45 |
| Market Cap | $162M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -27.15% |
| Return on Invested Capital | -32.65% |
| Return on Assets | -28.35% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARCT · ASMB · ENTA · FHTX · HUMA · NAUT · PYXS
Explore sector: Healthcare · Biotechnology
More sections of IMRX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks